Document Detail

The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
MedLine Citation:
PMID:  19765430     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The administration of interlukin-2 receptor antagonists for induction therapy has reduced the incidence of acute rejection episodes in kidney transplantation. Although some studies have investigated the efficacy of these monoclonal antibodies, there is little experience among Iranian kidney transplant recipients. MATERIALS AND METHODS: Forty-three patients randomly divided into 2 groups were prospectively followed for 3.4 years. Eighteen patients received 2 doses of basiliximab (group I) and another 25 patients received 5 doses of daclizumab (group II). The posttransplantation complications, last serum creatinine level, as well as graft and patient survival rates were compared to investigate the efficacy of these therapies. RESULTS: Among 43 patients, 11.6% experienced acute rejection episodes: 22.2% in group I and 4% in group II (P > .05). In this study, 4.6% of recipients underwent graft nephrectomy: 11.1% in group I and 4% in group II (P > .05). The mortality rate was 4.6%: 5.5% in group I and 4% in group II (P > .05). The mean serum creatinine level was 1.47 +/- 0.7 mg/dL. Although it was lower in group I, the difference was not significant. The 1-year graft and patient survival rates were 90.6% and 95.3%, respectively, with no significant differences between the groups. DISCUSSION: Although induction therapy with monoclonal antibodies may reduce the incidence of acute rejection episodes, graft and patient survival rates were unchanged compared with conventional therapies. Also, there were no significant differences between the results of induction therapy with basiliximab and daclizumab.
G H Naderi; D Mehraban; M R Ganji; M Jafarpouriani; A H Latif
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Transplantation proceedings     Volume:  41     ISSN:  1873-2623     ISO Abbreviation:  Transplant. Proc.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-21     Completed Date:  2010-01-11     Revised Date:  2010-03-03    
Medline Journal Info:
Nlm Unique ID:  0243532     Medline TA:  Transplant Proc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2768-71     Citation Subset:  IM    
Department of Kidney Transplantation, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Creatinine / blood
Dose-Response Relationship, Drug
Drug Administration Schedule
Graft Rejection / epidemiology
Graft Survival / drug effects,  physiology
Immunoglobulin G / therapeutic use*
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / immunology*,  mortality
Living Donors
Middle Aged
Prospective Studies
Recombinant Fusion Proteins / therapeutic use*
Survival Rate
Tissue Donors
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Recombinant Fusion Proteins; 0/basiliximab; 152923-56-3/daclizumab; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Preemptive living donor renal transplantation: a single-center experience.
Next Document:  Living or deceased donor kidney transplantation: a comparison of results and survival rates among Ir...